Trial Profile

Phase III trial of citrate/heparin/taurolidine (Neutrolin) for the prevention of catheter-related infections in cancer patients receiving total parenteral nutrition

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 01 Oct 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Citrate/heparin/taurolidine (Primary)
Indications Bacterial infections; Catheter infections; Catheter thrombosis; Mycoses
Focus Registrational; Therapeutic Use
Acronyms LOCK-IT 200
Sponsors CorMedix

15 Sep 2016 According to CorMedix media release, company may submit this and the other study (700250714) to the FDA for potential approval for both patient populations.
05 Aug 2016 According to a CorMedix media release, company anticipates a meeting with the FDA to finalize the protocol in 4Q 2016.
11 May 2016 According to a CorMedix media release, the company is planning to initiate pharmacoeconomic studies within LOCK-IT 100 and LOCK-IT 200 studies.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com